Abstract:Retinoid X receptor (RXR) plays a crucial role in the cross talk between retinoid receptors and other hormone receptors including the orphan receptor TR3, forming different heterodimers that transduce diverse steroid/thyroid hormone signaling. Here we show that RXRα exhibits nucleocytoplasmic shuttling in MGC80-3 gastric cancer cells and that RXRα shuttling is energy-dependent through a nuclear pore complex (NPC)-mediated pathway for its import and an intact DNA binding domain-mediated pathway for its export. In the presence of its ligand 9-cis retinoic acid, RXRα was almost exclusively located in the cytoplasm. More importantly, we also show that RXRα acts as a carrier to assist translocation of TR3, which plays an important role in apoptosis. Both RXRα and TR3 colocalized in the nucleus; however, upon stimulation by 9-cis retinoic acid they cotranslocated to the cytoplasm and then localized in the mitochondria. TR3 export depends on RXRα, as in living cells GFP-TR3 alone did not result in export from the nucleus even in the presence of 9-cis retinoic acid, whereas GFP-TR3 cotransfected with RXRα was exported out of the nucleus in response to 9-cis retinoic acid. Moreover, specific reduction of RXRα levels caused by anti-sense RXRα abolished TR3 nuclear export. In contrast, specific knockdown of TR3 by antisense-TR3 or TR3-siRNA did not affect RXRα shuttling. These results indicate that RXRα is responsible for TR3 nucleocytoplasmic translocation, which is facilitated by the RXRα ligand 9-cis retinoic acid. In addition, mitochondrial TR3, but not RXRα, was critical for apoptosis, as TR3 mutants that were distributed in the mitochondria induced apoptosis in the presence or absence of 9-cis retinoic acid. These data reveal a novel aspect of RXRα function, in which it acts as a carrier for nucleocytoplasmic translocation of orphan receptors.

Centrosomal Localization of RXRα Promotes PLK1 Activation and Mitotic Progression and Constitutes a Tumor Vulnerability

Design, synthesis and biological evaluation of acyl hydrazones-based derivatives as RXRα-targeted anti-mitotic agents

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

RXRα provokes tumor suppression through p53/p21/p16 and PI3K-AKT signaling pathways during stem cell differentiation and in cancer cells

Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis

RXR Signaling Targeted Cancer Therapy

Regulation of drug resistance by human pregnane X receptor in breast cancer.

Supplementary Data Legends from Cervical Cancer Growth is Regulated by a C-Abl–plk1 Signaling Axis

RXRα Acts As a Carrier for TR3 Nuclear Export in a 9-Cis Retinoic Acid-Dependent Manner in Gastric Cancer Cells

Discovery of bipyridine amide derivatives targeting p RXRα-PLK1 interaction for anticancer therapy

Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma

Deciphering the Performance of Polo-Like Kinase 1 in Triple-Negative Breast Cancer Progression According to the Centromere Protein U-phosphorylation Pathway.

RPL23 Links Oncogenic RAS Signaling to P53-Mediated Tumor Suppression

Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition

Pharmacological Modulation of RB1 Activity Mitigates Resistance to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.

Inhibition of the PLK1‐Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer

The phosphorylated retinoid X receptor-α promotes diethylnitrosamine-induced hepatocarcinogenesis in mice through the activation of β-catenin signaling pathway

Loss of keratinocytic RXRα combined with activated CDK4 or oncogenic NRAS generates UVB-induced melanomas via loss of p53 and PTEN in the tumor microenvironment

Cell cycle-dependent phosphorylation of PRPS1 fuels nucleotide synthesis and promotes tumorigenesis.

Resveratrol Activates DNA Damage Response Through Inhibition of Polo-Like Kinase 1 (PLK1) in Natural Killer/t Cell Lymphoma

CDK9 recruits HUWE1 E3 ligase to degrade RARα in a kinase independent manner and offers therapeutic opportunities for cutaneous T-cell lymphoma